John J. P. Kastelein

发表

Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia.

J. Kastelein, E. Stroes, S. Tsimikas, 2005, Arteriosclerosis, thrombosis, and vascular biology.

Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia

R. Hegele, E. Stroes, M. Hosseini, 2012, Journal of internal medicine.

Common C-to-T substitution at position -480 of the hepatic lipase promoter associated with a lowered lipase activity in coronary artery disease patients.

J. Jukema, A. V. D. van den Ouweland, J. Kastelein, 1997, Arteriosclerosis, thrombosis, and vascular biology.

CETP gene variation: relation to lipid parameters and cardiovascular risk

J. Jukema, J. Kastelein, G. Hovingh, 2004, Current opinion in lipidology.

Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis.

A. Zwinderman, A. Henney, M. Beekman, 1999, The American journal of cardiology.

−455G/A Polymorphism of the β-Fibrinogen Gene is Associated With the Progression of Coronary Atherosclerosis in Symptomatic Men

A. Zwinderman, J. Kastelein, J. Jukema, 1998 .

Effects of Six APOA5 Variants, Identified in Patients With Severe Hypertriglyceridemia, on In Vitro Lipoprotein Lipase Activity and Receptor Binding

N. Delsaux, P. Talmud, J. Kastelein, 2008, Arteriosclerosis, thrombosis, and vascular biology.

Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?

N. Nurmohamed, M. Ditmarsch, John J. P. Kastelein, 2021, Cardiovascular research.

Increasing high-density lipoprotein cholesterol through cholesteryl Ester transfer protein inhibition: a next step in the fight against cardiovascular disease?

J. Kastelein, J. Kuivenhoven, W. A. van der Steeg, 2005, Current drug targets. Cardiovascular & haematological disorders.

Gene therapy for genetic lipoprotein lipase deficiency: from promise to practice.

J. Twisk, J. Kastelein, E. Stroes, 2005, The Netherlands journal of medicine.

Gonadal steroids, gonadotropins and DHEAS in young adults with familial hypercholesterolemia who had initiated statin therapy in childhood.

A. V. van Trotsenburg, F. Wijburg, J. Kastelein, 2015, Atherosclerosis.

Cholesteryl Ester Transfer Protein ( CETP ) Inhibition Beyond Raising High-Density Lipoprotein Cholesterol Levels Pathways by Which Modulation of CETP Activity May Alter Atherogenesis

J. Kastelein, S. Boekholdt, E. Stroes, 2006 .

A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease.

A. Brownlie, A. Zwinderman, M. Hayden, 2004, Journal of the American College of Cardiology.

Modulation of Plasma Fibrinogen Levels by Ciprofibrate and Gemfibrozil in Primary Hyperlipidaemia

J. Kastelein, C. Kluft, M. D. de Maat, 1994, Thrombosis and Haemostasis.

Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels.

J. Boer, P. de Knijff, J. Kastelein, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia

C. Cannon, D. Kereiakes, P. Minini, 2016, Coronary artery disease.

Human ATP–Binding Cassette G1 Controls Macrophage Lipoprotein Lipase Bioavailability and Promotes Foam Cell Formation

J. Jukema, J. Kastelein, T. V. van Berkel, 2012, Arteriosclerosis, thrombosis, and vascular biology.

Two novel molecular defects in the LCAT gene are associated with fish eye disease.

J. Kastelein, P. Demacker, A. Stalenhoef, 1996, Arteriosclerosis, thrombosis, and vascular biology.

Plasma and fibroblasts of Tangier disease patients are disturbed in transferring phospholipids onto apolipoprotein A-I.

A. von Eckardstein, G. Assmann, J. Kastelein, 1998, Journal of lipid research.